Latest valproic acid Stories
The approval letter allows clinical development of DP-VPA through Phase 3 for epilepsy REHOVOT, Israel, April 14, 2015 /PRNewswire/ -- D-Pharm Ltd., (TASE: DPRM)
An Innovative Approach That Puts Clinicians in Charge MAPLE GROVE, Minn., July 28, 2014 /PRNewswire/ -- Upsher-Smith Laboratories,
Transparency Market Research added a new report "Global Epilepsy Therapeutics Market: Industry Analysis, Size, Share, Growth and Forecast 2019" to its report store.
First Branded Product in CNS Portfolio Now Available MAPLE GROVE, Minn., June 30, 2014 /PRNewswire/ -- Upsher-Smith
Flood Law Group announced today that they are available to investigate the claims of parents of children who suffer from birth defects that are possibly linked to the prescription drug Depakote.
Qudexy(TM) XR Offers Newest Option for Managing Certain Seizure Disorders and Marks the Company's Entrance into the Epilepsy Therapeutic Area MAPLE GROVE, Minn., March 12, 2014 /PRNewswire/
A new study finds that the epilepsy drug levetiracetam appears not to be associated with thinking, movement and language problems for preschool children born to mothers who took the drug during pregnancy, although the drug valproate was associated with some difficulties in preschoolers.
50 years after valproate was first discovered, research published today in the journal Neurobiology of Disease, reports how the drug works to block seizure progression.
On August 17, Bloomberg published that a federal court complaint was filed accusing Abbott Labs of racketeering in an effort to promote Depakote for unapproved uses.